Toggle navigation image image
Toggle navigation logologo
image image
  • About Inflarx
    • Leadership Team
    • Board
    • Company History
    • Vision
  • R&D
    • About Complement
    • About C5A
    • Technology
    • Pipeline
    • Clinical Development
      • Hidradenitis Suppurativa
        • Shine Study FAQ
      • ANCA-Associated Vasculitis
      • Pyoderma Gangraenosum
      • COVID-19
      • cSCC
    • Clinical Trials
    • Publications & Posters
  • Investors
    • Press Releases
    • Events & Presentations
    • Financial Information
    • Share Information
    • Analyst Coverage
    • Corporate Governance
    • Annual/Extraordinary General Meetings
    • E-mail alerts
  • Career
    • Open Positions
      • Office Manager (m/w/d)
      • Controller (m/w/d)

Bruce Burnett

  • Home
  • About Inflarx
  • Leadership Team
  • Bruce Burnett
image

Dr. Bruce P. Burnett

VP, Head of Medical Affairs

Dr. Bruce P. Burnett joined InflaRx in 2020 as Head of US Regulatory and Medical Affairs. He received his BS degrees in biology and chemistry from Eastern Washington University and his Master’s in Philosophy in biochemistry and PhD in molecular biophysics and biochemistry from Yale University.  He is the recipient of several NIH as well as SBIR grants and has served on the ad hoc study section for review of NIH SBIR awards. Dr. Burnett has been in the pharmaceutical industry for over 25 years spending his first 8 years in drug discovery and then the last 17 in medical affairs, regulatory and compliance. His disease state experience includes women’s health (contraception, HRT-menopausal symptom relief, aesthetics-venous disease, osteopenia/osteoporosis), gastroenterology (irritable bowel syndrome, HIV-enteropathy, Crohn’s disease, ulcerative colitis, chronic diarrhea, GERD), rheumatology (osteoarthritis, rheumatoid arthritis), vascular disease (ANCA-AAV, chronic venous insufficiency, deep vein thrombosis and hemorrhoids), dermatology (hidradenitis suppurativa, pyoderma grangenosum, cutaneous squamous cell carcinoma, superficial bacterial and fungal infections, pruritus, acne, plaque psoriasis), infectious disease (HIV, GI infections-H. pylori and C. difficile, endemic/systemic fungal infections) and pulmonology (COVID-19, antifungal prophylaxis in lung and bone marrow transplant patients). Dr. Burnett supports the development of new chemical entities as well as collaboration with the clinical department to advance InflaRx’s clinical programs through interactions with thought leaders in each field.

Quick Links
  • Impressum
  • Privacy
  • Technology
  • News
  • Career
  • Disclaimer
  • Contact
  • Newsletter
  • Member area
Contact Jena

InflaRx N.V. / InflaRx GmbH
Winzerlaer Str. 2
07745 Jena

+49 3641 508 180

info@inflarx.de

InflaRx on Linkedin

Contact Munich

InflaRx N.V. / InflaRx GmbH
Fraunhoferstraße 22
82152 Martinsried

+49 89 414 189 78 00

info@inflarx.de

Contact Ann Arbor

InflaRx Pharmaceuticals Inc.
600 S. Wagner Rd.
Ann Arbor, MI 48103

info@inflarx.de

© Copyright 2017 All Rights Reserved.
  • Developed by Ementals